Eli Lilly's (LLY) Alzheimer's disease drug, Kisunla (donanemab), wins FDA approval. Kisunla will be the second drug on the market to treat the...
Vous n'êtes pas connecté
The Subject Expert Committee (SEC), which advises the national drug regulator on drugs and trials approval matters, has recommended grant of permission for import and marketing of Eli Lilly's weight loss drug
Eli Lilly's (LLY) Alzheimer's disease drug, Kisunla (donanemab), wins FDA approval. Kisunla will be the second drug on the market to treat the...
July 2 - The U.S. Food and Drug Administration on Tuesday gave a green light to Eli Lilly's LLY.N donanemab for patients with early Alzheimer's,...
Peter Obi, has recommended that capital punishment be handed out to drug traffickers, as a way of stemming the tide of the menace in Nigeria. Obi made...
On July 3, the Prime Minister made the following statement to Parliament on the Strategic Services Agency (SSA): Madam Speaker, I am authorised by...
The drug, Kisunla, made by Eli Lilly, is the latest in a new class of treatments that could modestly slow cognitive decline in initial stages of the...
PTC Therapeutics (PTCT) falls as the EC's advisory committee adopts a negative opinion regarding the renewal of the conditional marketing approval of...
The stock market is salivating over the money-making potential in the weight-loss wonder drug. Are we back in the ’70s?
The stock market is salivating over the money-making potential in the weight-loss wonder drug. Are we back in the ’70s?
The hype is enormous: A new weight-loss drug is being aggressively marketed on social media – promising patients a quick fix for obesity. But...
WEDNESDAY, July 3, 2024 -- Trendy weight-loss drugs appear to increase the risk of a rare and potentially blinding eye condition, a new study...